Oncology News

Results of a prospective study showed that treatment with direct-acting antivirals for hepatitis C correlated with significantly reduced risks for hepatocellular carcinoma and mortality, according to a study published in The Lancet.

Among the three largest Hispanic population subgroups, researchers found high levels of heterogeneity in chronic liver disease-related mortality patterns, according to a recently published study.

Patients undergoing direct-acting antiviral therapy for hepatitis C who had non-characterized liver nodules had a higher risk for hepatocellular carcinoma within a short follow-up time than other patients, according to a recently published study.

Eureka Therapeutics announced that the FDA has cleared its investigational new drug application for ET140202 ARTEMIS T-cell therapy for patients with hepatocellular carcinoma who are positive for alpha-fetoprotein, according to a press release.

Patients who underwent liver transplantation demonstrated an increased trend toward developing colon cancer and non-Hodgkin lymphoma, according to a press release and data presented at this year’s American College of Gastroenterology Annual Scientific Meeting.

Recently published studies have demonstrated new developments in the testing, diagnosis and treatment of gastrointestinal and liver cancers.

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not receive DAA therapy, according to a study published in Gastroenterology.

As cancer rates continue to rise throughout the U.S. and internationally, researchers have focused on defining factors and demographics correlated with a higher risk for hepatocellular carcinoma and extrahepatic liver cancer to guide clinical practice.

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

Exelixis has announced it has received FDA approval for Cabometyx to treat patients with hepatocellular carcinoma who previously underwent treatment with Nexavar, according to a press release.